Loading clinical trials...
Loading clinical trials...
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
Patients suffering from stage IV breast cancer undergoing a systemic treatment including: molecular targeted therapy, conjugated antibodies (ADCs), monoclonal antibodies, tyrosine kinase inhibitors (TKI), immunotherapy (ICIs), who are candidates for a radiation treatment (both palliative or curative), after being informed about the study and giving written informed consent, will be considered eligible for this observational study. This study aims to prospectively analyze the tolerance profile of radiation treatments performed during new generation systemic therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Radiation Oncology Department Fondazione Policlinico Campus BioMedico
Rome, Italy, Italy
Start Date
May 17, 2023
Primary Completion Date
May 17, 2029
Completion Date
May 17, 2029
Last Updated
June 15, 2025
300
ESTIMATED participants
Radiotherapy
RADIATION
Lead Sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
NCT04550494
NCT04704661
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions